Who was studied, and how
Four numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 16 other studies
4,256people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
empagliflozin 10 mg as add-on to metformin
placebo as add-on to metformin
Lowered long-term blood sugar−0.57
randomisedThe trial randomly assignedassigned by chance
empagliflozin 10 mg as add-on to metformin
active comparators (sitagliptin, linagliptin, glimepiride) as add-on to metformin
No clear effect on long-term blood sugar−0.10
randomisedthe abstract, start to end
… [10 mg: weighted mean difference (WMD) -0.57 %; 95 % confidence interval (CI) -0.65 to -0.49 %, P < 0.00001; 25 mg: …
… a similar reduction in HbA1c [WMD -0.10 %; 95 % CI -0.23 to 0.03 %, P = 0.13], while 25 mg of EMPA provided a significantly greater reduction in HbA1c [WMD -0.13 %; 95 % CI -0.20 to -0.06 %, …
← favours treatmentfavours comparator →
could be chanceGlycated haemoglobin (HbA1c)empagliflozin 10 mg as add-on to metformin vs placebo as add-on to metformin
−0.57−0.65 to −0.49
HbA1cempagliflozin 10 mg as add-on to metformin vs active comparators (sitagliptin, linagliptin, glimepiride) as add-on to metformin
−0.10−0.23 to 0.03
Glycated haemoglobin (HbA1c)empagliflozin 25 mg as add-on to metformin vs placebo as add-on to metformin
−0.65−0.72 to −0.57
HbA1cempagliflozin 25 mg as add-on to metformin vs active comparators (sitagliptin, linagliptin, glimepiride) as add-on to metformin
−0.13−0.20 to −0.06
MetforminSGLT2 inhibitorsGlycemic controlAdverse events & safety
Metformin × adverse events & safetyharms?mixed
unlikelylikely
0.27not counted
SGLT2 inhibitors × adverse events & safetyharms?mixed
unlikelylikely
0.00not counted
← favours treatmentfavours comparator →
1 / 6